Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Harmony Biosciences Holdings (HRMY) EBITDA (2019 - 2025)

Harmony Biosciences Holdings' EBITDA history spans 7 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, EBITDA fell 54.17% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $159.0 million, up 9.21%, while the annual FY2025 figure was $159.0 million, 9.21% up from the prior year.
  • EBITDA for Q4 2025 was $22.5 million at Harmony Biosciences Holdings, down from $51.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $87.8 million in Q3 2022 and bottomed at -$9.6 million in Q3 2021.
  • The 5-year median for EBITDA is $31.7 million (2023), against an average of $33.3 million.
  • The largest annual shift saw EBITDA tumbled 192.68% in 2021 before it soared 1012.62% in 2022.
  • A 5-year view of EBITDA shows it stood at $22.7 million in 2021, then soared by 113.68% to $48.5 million in 2022, then crashed by 44.11% to $27.1 million in 2023, then soared by 80.8% to $49.0 million in 2024, then tumbled by 54.17% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's EBITDA are $22.5 million (Q4 2025), $51.0 million (Q3 2025), and $39.8 million (Q2 2025).